Intercept Pharmaceuticals Inc (ICPT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Intercept Pharmaceuticals Inc (ICPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9799
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company owns worldwide rights to OCA except for China, Japan and Korea, where the rights were exclusively licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon) along with an option to exclusively license OCA in certain other Asian countries. The product is also under development for the treatment of various other liver diseases. Intercept’s other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US.

Intercept Pharmaceuticals Inc (ICPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Intercept Pharma Raises US$30 Million In Series C Financing 10
Partnerships 12
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept Pharma Enters into Research Agreement with University of Perugia 13
Equity Offering 14
Intercept Pharma Prices Private Placement of Shares for USD100 Million 14
Intercept Pharma Prices Public Offering of Shares for USD150 Million 16
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 18
Intercept Pharma Raises USD202 Million in Public Offering of Shares 20
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 22
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 24
Intercept Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$86 Million 26
Debt Offering 28
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 28
Intercept Pharmaceuticals Inc – Key Competitors 30
Intercept Pharmaceuticals Inc – Key Employees 31
Intercept Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Oct 31, 2018: Intercept Pharmaceuticals reports third quarter 2018 financial results and provides business update 34
Aug 02, 2018: Intercept Pharmaceuticals reports second quarter 2018 financial results and provides business update 36
May 08, 2018: Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update 38
Feb 14, 2018: Intercept Pharmaceuticals Reports Net Sales Of $129.2 Million For The Year Ended December 31, 2017 40
Jul 31, 2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 43
May 04, 2017: Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 45
Feb 23, 2017: Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update 47
Corporate Communications 50
Nov 27, 2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intercept Pharma Raises US$30 Million In Series C Financing 10
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept Pharma Enters into Research Agreement with University of Perugia 13
Intercept Pharma Prices Private Placement of Shares for USD100 Million 14
Intercept Pharma Prices Public Offering of Shares for USD150 Million 16
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 18
Intercept Pharma Raises USD202 Million in Public Offering of Shares 20
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 22
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 24
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$86 Million 26
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 28
Intercept Pharmaceuticals Inc, Key Competitors 30
Intercept Pharmaceuticals Inc, Key Employees 31
Intercept Pharmaceuticals Inc, Other Locations 32
Intercept Pharmaceuticals Inc, Subsidiaries 32

List of Figures
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Intercept Pharmaceuticals Inc (ICPT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dako AS-製薬・医療分野:企業M&A・提携分析
    Summary Dako A/S (Dako Denmark), a subsidiary of Agilent Technologies Inc is a diagnostic company. The company’s products include diagnostic antibodies, reagents and kits, software related products, instruments and related products, clone products, and synonym products. It also provides immunohistoc …
  • Atlantic Airways P/F:戦略・SWOT・企業財務分析
    Atlantic Airways P/F - Strategy, SWOT and Corporate Finance Report Summary Atlantic Airways P/F - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • EnerMech Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary EnerMech Ltd (EnerMech) is a provider of oilfield services. The company offers cranes and lifting services, hydraulic products and services, pipeline and umbilicals services, valve services, equipment rental, training services and industrial services. Its pipeline and umbilical services comp …
  • RPC Group PLC:企業の戦略・SWOT・財務情報
    RPC Group PLC - Strategy, SWOT and Corporate Finance Report Summary RPC Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • The Pep Boys – Manny, Moe & Jack of California:企業の戦略的SWOT分析
    The Pep Boys - Manny, Moe & Jack of California - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates:企業の戦略・SWOT・財務情報
    Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report Summary Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Summit Hotel Properties Inc:企業のM&A・事業提携・投資動向
    Summit Hotel Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Summit Hotel Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Enerjisa Enerji Uretim AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from natural gas, lignite coal, hydro, and wind sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …
  • Murphy Oil Corporation:企業の戦略・SWOT・財務分析
    Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • K3 Business Technology Group plc (KBT):企業の財務・戦略的SWOT分析
    Summary K3 Business Technology Group plc (K3 BTG) is an information technology company that provides integrated business systems. The company offers products including axis fashion, fresh dynamics, MS dynamics AX, MS dynamics NAV, pebblestone fashion, sage, and syspro. Its services comprise CRM, ERP …
  • Compass Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Compass Therapeutics LLC (Compass Therapeutics) is a biotechnology company that strives to develop transformational therapies for cancer, inflammation and autoimmune diseases. The company focuses on the discovery of antibody drug candidates that involve all targets in the complex immune func …
  • AMC Entertainment Holdings, Inc.:企業のM&A・事業提携・投資動向
    AMC Entertainment Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AMC Entertainment Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • LIncoln Electric Holdings Inc:企業のM&A・事業提携・投資動向
    LIncoln Electric Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LIncoln Electric Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Guardant Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection …
  • Endurance Wind Power Inc.-エネルギー分野:企業M&A・提携分析
    Summary Endurance Wind Power Inc. (Endurance) designs, manufactures and markets wind turbines. It offers remote monitoring services through EnduranceRemote Interface Centre (ERIC) proprietary system which provides real-time performance data to check wind speed and monitor the turbine’s operational s …
  • Ageas NV:企業の戦略・SWOT・財務情報
    Ageas NV - Strategy, SWOT and Corporate Finance Report Summary Ageas NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Intra-Cellular Therapies Inc (ITCI):企業の財務・戦略的SWOT分析
    Summary Intra-Cellular Therapies Inc (ITI) is a novel drug manufacturer. The company offers product platform such as ITCI Pipeline that includes lumateperone, ITI-007 platform, PDE inhibitor platform and drug discovery platform. The company’s lead product candidate ITI-007-lumateperone is to treat s …
  • UCB Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary UCB Inc (UCB), a subsidiary of UCB SA, is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, meta …
  • Suncorp Group Ltd:企業のM&A・事業提携・投資動向
    Suncorp Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Suncorp Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Consolidated Edison, Inc.:企業の戦略・SWOT・財務分析
    Consolidated Edison, Inc. - Strategy, SWOT and Corporate Finance Report Summary Consolidated Edison, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆